CT-0525

Carisma Therapeutics Inc · Phase 1 active Small molecule

At a glance

Generic name	CT-0525
Sponsor	Carisma Therapeutics Inc
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CT-0525 CI brief — competitive landscape report
CT-0525 updates RSS · CI watch RSS
Carisma Therapeutics Inc portfolio CI